Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Study for Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed 24 weeks of participation in Study H9B-MC-BCDO or Study H9B-MC-BCDV, or have completed 100 weeks of participation in Study H9B-MC-BCDM~* Woman must not be pregnant, breastfeeding, or become pregnant during the study~Exclusion Criteria:~* Current presence of a serious disorder or illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 120 milligrams (mg) of LY2127399 (Type: EXPERIMENTAL): Given every 4 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 240 mg loading dose when initiating treatment.~Or~Given every 4 weeks for 168 weeks for those participants from Study BCDM.
- 90 mg LY2127399 (Type: EXPERIMENTAL): Given every 2 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 180 mg loading dose when initiating treatment.~Or~Given every 2 weeks for 168 weeks for those participants from Study BCDM.

Based on this trial design, predict the completion outcome and termination type (if applicable).